BHVN250117P25000
- 0.07
- 0.000.00%
Biohaven Newsroom
Beam Upgraded by Bernstein Ahead of AATD Data
Bernstein Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $63
Biohaven Insider Bought Shares Worth $1,042,393, According to a Recent SEC Filing
H.C. Wainwright Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Cantor Fitzgerald Reiterates Overweight on Biohavento Overweight
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $56 to $69
HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Promising Drug Pipeline and Strategic Progress Position Biohaven Ltd. for Growth
Biohaven Ltd.'s Promising Pipeline and Strategic Partnerships Drive Buy Recommendation
Biohaven Announces Several Clinical And Regulatory Milestones
Biohaven's BHV-1300 Achieves Advances in Targeted IgG Reduction Trials
Express News | Biohaven Ltd - Bhv-1300 Safe and Well Tolerated in Phase 1
Express News | Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted Igg Reductions in the Lowest Subcutaneous Dose Tested; Announces Nda Submission for Troriluzole in SCA and Provides Other Key Program Updates
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025
Biohaven Said It Is Presenting Expanded Safety Data From BHV-7000 Multiple-dose Studies At The American Epilepsy Society 2024 Annual Meeting
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $61
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
Express News | Biohaven Ltd : RBC Raises Target Price to $61 From $58